Shi Xu1. 1. Scientific Development Manager, Discovery Biology, GenScript USA Inc., 860 Centennial Ave., Piscataway, New Jersey, 08854, USA. ben.xu@genscript.com.
Abstract
PURPOSE: This review discusses the molecular mechanism involved in the targeting and delivery of antibody-drug conjugates (ADCs), the new class of biopharmaceuticals mainly designed for targeted cancer therapy. METHODS: this review goes over major progress in preclinical and clinical studies of ADCs, in the past 5 years. RESULTS: The pharmacokinetics and pharmacodynamics of ADCs involve multiple mechanisms, including internalization of ADCs by target cells, intracellular trafficking, release of conjugated drugs, and payload. CONCLUSION: These mechanisms actually jointly determine the efficacy of ADCs. Therefore, the optimization of ADCs should take them as necessary rationales.
PURPOSE: This review discusses the molecular mechanism involved in the targeting and delivery of antibody-drug conjugates (ADCs), the new class of biopharmaceuticals mainly designed for targeted cancer therapy. METHODS: this review goes over major progress in preclinical and clinical studies of ADCs, in the past 5 years. RESULTS: The pharmacokinetics and pharmacodynamics of ADCs involve multiple mechanisms, including internalization of ADCs by target cells, intracellular trafficking, release of conjugated drugs, and payload. CONCLUSION: These mechanisms actually jointly determine the efficacy of ADCs. Therefore, the optimization of ADCs should take them as necessary rationales.
Entities:
Keywords:
Antibody drug conjugate; Internalization; Linker; Recycling; Trafficking
Authors: R V Chari; B A Martell; J L Gross; S B Cook; S A Shah; W A Blättler; S J McKenzie; V S Goldmacher Journal: Cancer Res Date: 1992-01-01 Impact factor: 12.701
Authors: P F Bross; J Beitz; G Chen; X H Chen; E Duffy; L Kieffer; S Roy; R Sridhara; A Rahman; G Williams; R Pazdur Journal: Clin Cancer Res Date: 2001-06 Impact factor: 12.531
Authors: Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter Journal: Nat Biotechnol Date: 2003-06-01 Impact factor: 54.908